DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC65682 · Updated 24 October 2026

RCB-4-8
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
RCB-4-830Ionizable lipid
DOTAP39Additional lipid components
Cholesterol30Sterol
C14-PEG20001PEG lipid
Reported total100Source values retained
Formulation calculator unavailable. A calculation is not enabled where component molecular weights or a fixed molar recipe are unverified. Selected pulmonary formulation contains DOTAP. The 35:16:46.5:2.5 DOPE screening recipe is separate. Exact C14-PEG2000 commercial mapping and N/P remain unverified. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
10 mM citrate, pH 3.0.
Luciferase mRNA; separate Cre and Cas9/sgRNA studies
Intratracheal
0.125, 0.25 and 0.5 mg/kg mLuc in the dose-response comparison
C57BL/6J mice
Microfluidic mixing for in vivo RCB-4-8, aqueous:ethanol 3:1; dialysis against PBS using 20 kDa MWCO at 4 C for 6 h.

Literature-reported performance for the cited formulation

Literature-reportedApproximately 100-fold higher in the reported dose-response comparisonIntratracheal mLuc LNP; distinct helper formulations; not an IV targeting result · 6 hMain PDF p.2, Fig.1j and SI Fig.S8
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetCombinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. DOI: 10.1038/s41587-023-01679-x DOI: 10.1038/s41587-023-01679-x
Selected pulmonary formulation contains DOTAP. The 35:16:46.5:2.5 DOPE screening recipe is separate. Exact C14-PEG2000 commercial mapping and N/P remain unverified.

Primary article